Circulating Regulatory T Cells Expressing Tumor Necrosis Factor Receptor Type 2 Contribute to Sepsis-Induced Immunosuppression in Patients During Septic Shock.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
15 12 2021
Historique:
received: 07 03 2021
accepted: 17 05 2021
pubmed: 22 5 2021
medline: 27 1 2022
entrez: 21 5 2021
Statut: ppublish

Résumé

Septic shock remains a major cause of death that can be complicated by long-term impairment in immune function. Among regulatory T (Treg) cells, the tumor necrosis factor receptor 2 positive (TNFR2pos) Treg-cell subset endorses significant immunosuppressive functions in human tumors and a sepsis mouse model but has not been investigated during septic shock in humans. We prospectively enrolled patients with septic shock hospitalized in intensive care units (ICU). We performed immunophenotyping and functional tests of CD4+ T cells, Treg cells, and TNFR2pos Treg cells on blood samples collected 1, 4, and 7 days after admission to ICU. We investigated 10 patients with septic shock compared to 10 healthy controls. Although the proportions of circulating Treg cells and TNFR2pos Treg-cell subsets were not increased, their CTLA4 expression and suppressive functions in vitro were increased at 4 days of septic shock. Peripheral blood mononuclear cells from healthy donors cultured with serum from septic shock patients had increased CTLA4 expression in TNFR2pos Treg cells compared to TNFR2neg Treg cells. In patients with septic shock, CTLA4 expression and suppressive function were increased in circulating TNFR2pos Treg cells. We identify TNFR2pos Treg cells as a potential attractive target for therapeutic intervention.

Sections du résumé

BACKGROUND
Septic shock remains a major cause of death that can be complicated by long-term impairment in immune function. Among regulatory T (Treg) cells, the tumor necrosis factor receptor 2 positive (TNFR2pos) Treg-cell subset endorses significant immunosuppressive functions in human tumors and a sepsis mouse model but has not been investigated during septic shock in humans.
METHODS
We prospectively enrolled patients with septic shock hospitalized in intensive care units (ICU). We performed immunophenotyping and functional tests of CD4+ T cells, Treg cells, and TNFR2pos Treg cells on blood samples collected 1, 4, and 7 days after admission to ICU.
RESULTS
We investigated 10 patients with septic shock compared to 10 healthy controls. Although the proportions of circulating Treg cells and TNFR2pos Treg-cell subsets were not increased, their CTLA4 expression and suppressive functions in vitro were increased at 4 days of septic shock. Peripheral blood mononuclear cells from healthy donors cultured with serum from septic shock patients had increased CTLA4 expression in TNFR2pos Treg cells compared to TNFR2neg Treg cells.
CONCLUSIONS
In patients with septic shock, CTLA4 expression and suppressive function were increased in circulating TNFR2pos Treg cells. We identify TNFR2pos Treg cells as a potential attractive target for therapeutic intervention.

Identifiants

pubmed: 34019653
pii: 6279776
doi: 10.1093/infdis/jiab276
doi:

Substances chimiques

CTLA-4 Antigen 0
Receptors, Tumor Necrosis Factor, Type II 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2160-2169

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Auteurs

Benjamin Jean Gaborit (BJ)

EA3826 Thérapeutiques Anti-Infectieuses, Nantes Université, Nantes, France.
Department of Infectious Diseases, Centre Hospitalier Universitaire Nantes, Nantes, France.
Centre Hospitalier Universitaire Nantes, INSERM, CIC 1413, Nantes, France.

Tanguy Chaumette (T)

EA3826 Thérapeutiques Anti-Infectieuses, Nantes Université, Nantes, France.

Marie Chauveau (M)

EA3826 Thérapeutiques Anti-Infectieuses, Nantes Université, Nantes, France.
Department of Infectious Diseases, Centre Hospitalier Universitaire Nantes, Nantes, France.
Centre Hospitalier Universitaire Nantes, INSERM, CIC 1413, Nantes, France.

Antoine Asquier-Khati (A)

EA3826 Thérapeutiques Anti-Infectieuses, Nantes Université, Nantes, France.
Department of Infectious Diseases, Centre Hospitalier Universitaire Nantes, Nantes, France.
Centre Hospitalier Universitaire Nantes, INSERM, CIC 1413, Nantes, France.

Antoine Roquilly (A)

EA3826 Thérapeutiques Anti-Infectieuses, Nantes Université, Nantes, France.
Surgical Intensive Care Unit, Centre Hospitalier Universitaire Nantes, Nantes, France.

David Boutoille (D)

EA3826 Thérapeutiques Anti-Infectieuses, Nantes Université, Nantes, France.
Department of Infectious Diseases, Centre Hospitalier Universitaire Nantes, Nantes, France.
Centre Hospitalier Universitaire Nantes, INSERM, CIC 1413, Nantes, France.

Régis Josien (R)

Centre de Recherche en Transplantation et Immunologie, Institut de Transplantation Urologie Néphrologie, UMR 1064, INSERM, Nantes Université, Nantes, France.
Laboratoire d'Immunologie, Centre d'Immunomonitorage Nantes-Atlantique, Centre Hospitalier Universitaire Nantes, Nantes, France.

Benoit L Salomon (BL)

Centre d'Immunologie et des Maladies Infectieuses, INSERM, CNRS, Sorbonne Université, Paris, France.

Karim Asehnoune (K)

EA3826 Thérapeutiques Anti-Infectieuses, Nantes Université, Nantes, France.
Surgical Intensive Care Unit, Centre Hospitalier Universitaire Nantes, Nantes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH